Literature DB >> 18407932

Cancer control activities in the Republic of Korea.

Keun-Young Yoo1.   

Abstract

South Korea has a population of 47.3 million. The whole population is covered by a mandatory social insurance system (the National Health Insurance Program) that is financed through the contributions paid by the insured and their employers. Cancer has been the leading cause of death in Korea since 1983. About 130 000 people develop cancer annually with 66 000 deaths in 2006. Cancer patients' 5-year survival rates between 1998 and 2002 were 37.8 and 57.0% for men and women, respectively. The five leading primary cancer sites were stomach, lung, liver, colon and rectum, and bladder among males, whereas the most common cancers were stomach, breast, colon and rectum, uterine cervix and lung among females. With the rapidly aging population, reducing cancer burden at the national level has become one of the major political issues in Korea. The government formulated its first 10-year plan for cancer control in 1996. In 2000, the National Cancer Center was created and the Cancer Control Division was set up within the Ministry of Health and Welfare. The Cancer Control Act was legislated in 2003. Korea's major national cancer control programs are anti-smoking campaigns, hepatitis B virus vaccination, cancer registration and networking, promotion of R&D activities for cancer control, education and training for cancer control and prevention, operation of the national cancer information center, operation of the mass screening program for five common cancers, management of cancer patients at home, financial support for cancer patients and designation of regional cancer centers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407932     DOI: 10.1093/jjco/hyn026

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  77 in total

1.  Disparities in short-term and long-term all-cause mortality among Korean cancer patients with and without preexisting disabilities: a nationwide retrospective cohort study.

Authors:  Sang Min Park; Ki Young Son; Jae-Hyun Park; Belong Cho
Journal:  Support Care Cancer       Date:  2011-04-26       Impact factor: 3.603

2.  Factors associated with participation in colorectal cancer screening in Korea: the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV).

Authors:  Jun-Pyo Myong; Jin-Yong Shin; Su-Jin Kim
Journal:  Int J Colorectal Dis       Date:  2012-02-22       Impact factor: 2.571

3.  Performance of the fecal immunochemical test is not decreased by high ambient temperature in the rapid return system.

Authors:  Jae Myung Cha; Joung Il Lee; Kwang Ro Joo; Hyun Phil Shin; Jae Jun Park; Jung Won Jeun; Jun Uk Lim; Sang-Hyun Hwang
Journal:  Dig Dis Sci       Date:  2012-03-27       Impact factor: 3.199

4.  Gastric Cancer Screening in Common Variable Immunodeficiency.

Authors:  David K van der Poorten; Duncan McLeod; Golo Ahlenstiel; Scott Read; Avelyn Kwok; Cositha Santhakumar; Milan Bassan; Suzanne Culican; David Campbell; Sue W J Wong; Louise Evans; Bilel Jideh; Alisa Kane; Constance H Katelaris; Karuna Keat; Yanna Ko; Jessie A Lee; Sandhya Limaye; Ming Wei Lin; Ari Murad; Martina Rafferty; Dan Suan; Sanjay Swaminathan; Sean D Riminton; Catherine Toong; Lucinda J Berglund
Journal:  J Clin Immunol       Date:  2018-09-15       Impact factor: 8.317

5.  Differences in clinical presentation of non-small cell lung cancer in never-smokers versus smokers.

Authors:  Joo Young Lee; Im Ii Na; Seung-Hun Jang; Yong Il Hwang; Du Hwan Choe; Cheol Hyeon Kim; Heejong Baek
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

6.  Does Low Threshold Value Use Improve Proximal Neoplasia Detection by Fecal Immunochemical Test?

Authors:  Nam Hee Kim; Hyo-Joon Yang; Soo-Kyung Park; Jung Ho Park; Dong Il Park; Chong Il Sohn; Kyuyong Choi; Yoon Suk Jung
Journal:  Dig Dis Sci       Date:  2016-04-23       Impact factor: 3.199

7.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

8.  Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.

Authors:  Junshik Hong; Sun Young Kyung; Sang Pyo Lee; Jeong Woong Park; Sung Hwan Jung; Jae-Ik Lee; Se Hoon Park; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 2.884

9.  Hepatitis B vaccinations among Koreans: Results from 2005 Korea National Cancer Screening Survey.

Authors:  Hee-Soon Juon; Kui Son Choi; Eun-Cheol Park; Min-Son Kwak; Sunmin Lee
Journal:  BMC Infect Dis       Date:  2009-11-25       Impact factor: 3.090

10.  Increasing uptake of colorectal cancer screening in Korea: a population-based study.

Authors:  Kui Son Choi; Jae Kwan Jun; Hoo-Yeon Lee; Myung-Il Hahm; Jae Hwan Oh; Eun-Cheol Park
Journal:  BMC Public Health       Date:  2010-05-21       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.